By Brazil Stock Guide — Shares of Oncoclínicas (B3: ONCO3) have nearly doubled in a week, accompanied by a sharp surge in trading volume and renewed attention to a shareholder dispute whose potential value has been estimated at around R$6 billion — several times the company’s current market capitalization.
ONCO3 closed at R$0.56 on Aug. 11 and ended Tuesday, Aug. 18, at R$1.10, a gain of 96.4% in seven days. The stock rose about 43% in the last two trading sessions alone.
The magnitude of those percentage moves, however, needs to be viewed in the context of where the stock started.
Oncoclínicas had fallen into penny-stock territory after a prolonged decline, making relatively small moves in reais translate into outsized percentage swings. At R$0.56, for example, a change of just R$0.01 represented almost 1.8% of the share price.
Even after nearly doubling in a week and closing at R$1.10, ONCO3 remained about 77% below its 52-week high of R$4.89. Part of the dramatic rally, therefore, reflects an extremely depressed starting point.
Trading activity, however, has increased sharply alongside the share price. This week, 44.8 million shares changed hands on Monday and 46.6 million on Tuesday, compared with roughly 10 million shares per session between July 20 and Aug. 11. Recent daily volume has therefore been running at close to four times the level seen immediately before the rally.
The timeline calls for caution before attributing the entire move to the dispute over a potential mandatory tender offer, known in Brazil as an OPA. Expectations have grown that the board of Brazil’s Securities and Exchange Commission, the CVM, could consider the case next week.
O Globo reported that the regulator is expected to review on Aug. 25 an appeal over whether Centaurus Capital should be required to launch a tender offer for Oncoclínicas minority shareholders.
The date, however, has yet to appear on the CVM board’s official published agenda, which is typically released only a few days before each meeting.
Weak earnings hardly explain the rally on their own
The scale of the move is even more striking because the financial results released Friday do not point to a comparable improvement in Oncoclínicas’ operating fundamentals.
BTG Pactual described the second quarter as another “very weak” period for the company. Its report, however, makes no mention of the tender-offer dispute.
Oncoclínicas’ net revenue fell 29% from a year earlier to R$1.05 billion. Accounting EBITDA swung to a negative R$246 million from positive R$116 million in the same period of 2025, while the company posted a net loss of R$476 million.
Net debt, including M&A-related payables, ended the quarter at R$3.40 billion. Leverage rose to about 7.9 times net debt to adjusted trailing 12-month EBITDA, from 5.2 times in the first quarter.
The main positive in the results was R$158 million of operating cash flow, compared with a R$153 million outflow in the first quarter.
BTG, however, cautioned against reading too much into that improvement.
According to the bank, cash generation benefited from renegotiated payment terms with Oncoclínicas’ largest supplier, the normalization of receivables and a standstill agreement with creditors that suspended interest payments during the period.
The tender-offer optionality
It is against this backdrop that the shareholder dispute becomes increasingly relevant in explaining at least part of ONCO3’s new trading dynamics.
The controversy centers on a poison-pill provision in Oncoclínicas’ bylaws that requires a tender offer if an investor exceeds 15% of the company’s share capital.
Shareholders led by Latache, which is challenging the corporate reorganization, argue that Centaurus Capital emerged as a new direct shareholder in Oncoclínicas with a stake large enough to trigger the mandatory offer.
Centaurus and Goldman Sachs argue that the investment firm had already held an indirect economic interest in Oncoclínicas before the IPO and that the restructuring merely converted an existing indirect exposure into a direct shareholding.
The CVM’s technical staff accepted that interpretation and reaffirmed last Friday its view that the tender offer should not be required. The appeal will now be decided by the regulator’s board.
That is where the asymmetry becomes significant.
The potential value of the tender-offer dispute has been estimated at around R$6 billion. Importantly, that money would not go to Oncoclínicas itself and would not directly solve the company’s financial restructuring.
If the tender-offer obligation were ultimately recognized and an offer were launched, the proceeds would instead go to shareholders who chose to tender their shares.
For ONCO3, the effect is different.
With approximately 651.8 million shares outstanding, Tuesday’s R$1.10 close implies a market capitalization of about R$717 million. The R$6 billion estimate associated with the dispute is therefore worth more than eight times the company’s current equity value.
The possibility of an offer at a price far above the prevailing market price effectively gives ONCO3 an event-driven component tied to a regulatory outcome.
The next test for that thesis will be the publication of the CVM board’s official agenda — and confirmation of whether the appeal will in fact be heard on Aug. 25.
Leave a Reply